

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/017,905	ATTY. DOCKET NO.: B00801.70238.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: December 14, 2001	CONFIRMATION NO.: 7653
		APPLICANT: Ridker et al.	
Sheet 1 of 1		GROUP ART UNIT: 1646	EXAMINER: unknown



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PN	C1	El-Nawawy, A. et al., "Interleukin-1- β , Tumor Necrosis Factor- α , Insulin Secretion and Oral Glucose Tolerance in Non-Diabetic Siblings of Children with IDDM," <i>Indian J. Pediatr.</i> 1998; 65: 455-460.	
	C2	Kallmann, B.A., et al. "Cytokine secretion patterns in twins discordant for Type I diabetes," <i>Diabetologia</i> 1999; 42: 1080-1085.	
	C3	Kretowski, A. et al., "The immune markers of preclinical phase of type 1 diabetes mellitus. The role of cytokines, adhesion molecules and peripheral blood lymphocyte subpopulations in the pathogenesis and prediction of insulin-dependent diabetes," <i>Przegląd Lekarski</i> 2000; 57: (12) 736-742.	
	C4	Kretowski, A. et al., "In Vitro Secretion of Interleukin 2 and Expression of IL-2 Receptor in Peripheral Blood Lymphocytes in High Risk of Insulin-Dependent Diabetes Mellitus Subjects," <i>Archivum Immunologiae et Therapiae Experimentalis</i> 1999; 47: 45-49.	
	C5	Kretowski, A. et al., "Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor- α in peripheral whole blood of people at high risk of developing Type 1 diabetes and people with newly diagnosed Type 1 diabetes," <i>Diabetes Research and Clinical Practice</i> 2000; 47: 81-86.	
	C6	Szelachowska, M. et al., "Increased In Vitro Interleukin-12 Production by Peripheral Blood in High-Risk IDDM First Degree Relatives," <i>Horm Metab. Res.</i> 1997; 29: 168-171.	
PN	C7	PCT International Search Report for PCT/US01/48349, Date Search Completed: January 8, 2003.	

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 11/29/01
--------------------------------	-----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

RECEIVED

MAR 12 2003